Drugs / Monepantel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06177431 | Feb 2024 → May 2025 | motor neuron disorder | Neurizon Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT04894240 | Jun 2022 → Nov 2023 | motor neuron disorder | Neurizon Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monepantel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06177431 ↗ |
| Known as | Monepantel component of zolvix | ChEMBL registry synonym — accepted as the source's own label CHEMBL256563 ↗ |
| Known as | Zolvix | ChEMBL registry synonym — accepted as the source's own label CHEMBL256563 ↗ |
| Action | Inhibit | “monepantel shows off-target activity, inhibiting a cellular signaling system controlled by mammalian target of rapamycin (mTOR)” NCT04894240 ↗ |
| Modality | Small molecule | — CHEMBL256563 ↗ |
| Route | Oral | “oral monepantel administration” NCT04894240 ↗ |
| Target | MTOR | “as an mTOR inhibitor” NCT04894240 ↗ |